Prevalence of SARS-CoV-2 Genome in Tears of Asymptomatic and Moderately Symptomatic COVID-19 Patients

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04654325

Acronym

COVIDEYE

Enrollment

534

Registered

2020-12-04

Start date

2021-01-19

Completion date

2021-04-29

Last updated

2022-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV-2

Keywords

SARS-CoV-2, COVID19, conjunctiva, tears

Brief summary

To evaluate the prevalence of SARS-CoV-2 genome in patients with asymptomatic and moderately symptomatic COVID19.

Detailed description

Patients attending to the COVID19 screening facility of Paris South University hospital and willing to participate to the study will have both nasopharyngeal and conjunctival swab for SARS-CV-2 genome detection using PCR. The project will evaluate the prevalence of positive conjunctival swabs in patients with positive nasopharyngeal swab. These results will be corelated to symptoms of disease assessed with a standardized questionnaire.

Interventions

DIAGNOSTIC_TESTconjunctival swab

Patients will have conjunctival swab for SARS-CV-2 genome detection

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients receiving diagnostic nasopharyngeal PCR for COVID-19 as part of the usual care * Age ≥ 18. * Information and signature of consent * Affiliated with a social security scheme or entitled

Exclusion criteria

* Refusal to participate in the study * Eye surgery less than 3 months old * Unable to give informed consent * No coverage through the health insurance system * Patient under judicial protection * Patient on AME

Design outcomes

Primary

Measure	Time frame	Description
presence of SARS-CoV-2 genome in tears	at the end of the study, an average of 1 year	Prevalence of SARS-CoV-2 genome in tears

Secondary

Measure	Time frame	Description
presence of systemic symptoms evaluated at the time of making an appointment by a systematic standardized interrogation	at the end of the study, an average of 1 year	correlation between systemic symptoms (fever, chills, sweating, muscle aches, headache, runny or stuffy nose, cough, sore throat, asthenia, anosmia, agueusia, unusual shortness of breath, skin rash diarrhea, nausea vomiting) and positive conjunctival swab
assessement of viral load levels	at the end of the study, an average of 1 year	correlation between nasopharyngeal viral load and conjunctival load (indirectly assessed with cycle thresholds quantification method)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026